Why Bio-Reference Labs Shares Plunged

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of lab testing services specialist Bio-Reference Laboratories (Nasdaq: BRLI  ) sank 10% on Thursday after its quarterly results disappointed Wall Street.

So what: Bio-Reference's second-quarter results were actually in line with estimates -- EPS of $0.33 on revenue of $163.4 million versus the consensus of $0.32 and $161 million -- but given the stock's run-up over the past six months, it's clear that investors were expecting more. Expectations aside, however, management generated more revenue while improving margins, so Bio-Reference seems to have some decent operating momentum working in its favor.

Now what: I'd look into this plunge as a possible buy-in opportunity. "We continue to be paced by esoteric growth, but we have also been able to expand routine clinical testing into those same physician offices and have been able to achieve a more stable position in the physicians' offices," said CEO Dr. Marc Grodman. "Our sales force is continually infused with energy by our new offerings and we expect to leverage that energy into continued expansion around the country." With the stock down about 20% from its 52-week high and trading at a forward P/E of 11.5, now might be a good time to get in on that growth.

Interested in more info on Bio-Reference? Add it to your watchlist.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Bio-Reference. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.


Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 1906354, ~/Articles/ArticleHandler.aspx, 7/25/2014 5:19:31 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement